EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers

References

• Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancertherapy. Endocr Relat Cancer 2001;8:83–96.
   PubMed Web of Science ®Google Scholar
• Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98–110.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in Glioblastoma. Curr Opin Neurol 2012;25:774–9.
   PubMed Web of Science ®Google Scholar
• Patel R, Leung HY. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Current Pharm Des. 2012;18:2672–9.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550–65.
   PubMed Web of Science ®Google Scholar
• Mawrin C, Diete S, Treuheit T, et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol 2003;23:641–8.
   PubMedGoogle Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550–65.
   PubMed Web of Science ®Google Scholar
• Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (New York, NY) 2007;318: 287–90.
   Google Scholar
• Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 2012;12:197–209.
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with atruncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994;9:2313–20.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 2009;9:1087–98.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor And EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462–6.
   PubMed Web of Science ®Google Scholar
• Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962–70.
   PubMed Web of Science ®Google Scholar
• Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93: 1246–56
   PubMed Web of Science ®Google Scholar
• Hobbs J, Nikiforova MN, Fardo DW, et al. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol 2012;36:1186–93.
   Google Scholar
• Montano N, Cenci T, Martini M, et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia 2011;13:1113–21.
   PubMed Web of Science ®Google Scholar
• Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated Protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006;12:3935–41.
   PubMed Web of Science ®Google Scholar
• Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16:748–54.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27:1268–74.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2010;96:219–30.
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6:1167–74.
   PubMed Web of Science ®Google Scholar
• Lv S, Teugels E, Sadones J, et al. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol 2012;41:1029–35.
   PubMedGoogle Scholar
• Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid 2012;7:93–103.
   PubMedGoogle Scholar
• Chandramohan V, Bao X, Keir ST, et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res. 2013;19: 4717–27.
   PubMed Web of Science ®Google Scholar
• Fan Q-W, Cheng CK, Nicolaides TP, et al. A dual phosphoinositide-3-kinase alpha/mTOR Inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007;67:7960–5.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of Glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012–24.
   PubMed Web of Science ®Google Scholar
• Lal B, Goodwin CR, Sang Y, et al. EGFRvIII and c-Met pathway inhibitors synergize against PTEN null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 2009;8:1751–60.
   PubMed Web of Science ®Google Scholar
• Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004;63:700–7.
   PubMed Web of Science ®Google Scholar
• Viana-Pereira M, Lopes JM, Little S, et al. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res 2008;28:913–20.
   Google Scholar
• Yoshimoto K, Dang J, Zhu S, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 2008;14:488–93.
   PubMed Web of Science ®Google Scholar
• Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383–7.
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Montgomery RB, Sundareshan P, et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996;13:85–96.
   PubMed Web of Science ®Google Scholar
• Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008;10:619–24.
   PubMed Web of Science ®Google Scholar
• Del Vecchio CA, Giacomini CP, Vogel H, et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene 2013;32:2670–81.
   PubMed Web of Science ®Google Scholar
• Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011;71:4055–60.
   PubMed Web of Science ®Google Scholar
• Inda MM, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731–45.
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Sugiyama T, Narita Y, et al. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 2004;21:53–6.
   PubMedGoogle Scholar
• Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20:810–7.
   PubMed Web of Science ®Google Scholar